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ABSTRACT 
Cyclodextrins (CDs) are used in oral pharmaceutical formulations, by means of 
inclusion complexes formation, with the following advantages for the drugs: (1) 
solubility, dissolution rate, stability and bioavailability enhancement; (2) to modify the 
drug release site and/or time profile; and (3) to reduce or prevent gastrointestinal side 
effects and unpleasant smell or taste, to prevent drug-drug or drug-additive interactions, 
or even to convert oil and liquid drugs into microcrystalline or amorphous powders. A 
more recent trend focuses on the use of CDs as nanocarriers, a strategy that aims to 
design versatile delivery systems that can encapsulate drugs with better 
physicochemical properties for oral delivery. Thus, the aim of this work was to review 
the applications of the CDs and their hydrophilic derivatives on the solubility 
enhancement of poorly water soluble drugs in order to increase their dissolution rate and 
get immediate release, as well as their ability to control (to prolong or to delay) the 
release of drugs from solid dosage forms, either as complexes with the hydrophilic (e.g. 
as osmotic pumps) and/ or hydrophobic CDs.  New controlled delivery systems based 
on nanotechonology carriers (nanoparticles and conjugates) have also been reviewed.  
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Introduction 
 
Drugs need to be released from their carriers (formulations and/or delivery 
systems) in order to produce their therapeutic effects (1), and difficulties on the design 
of the formulation may arise depending on drugs’ solubility. Currently, many platforms 
are available for a prolonged or delayed releasing of highly water soluble drugs (2). 
However, if drugs are poorly water soluble, their formulation is more challenging 
(solubilization and/or particle engineering) especially when a controlled release drug 
profile is desired. For these drugs the absorption and bioavailability could be influenced 
by their intrinsic solubility and dissolution rate in the gastrointestinal (GI) tract. There 
are many strategies to enhance the solubility of poorly water soluble drugs in order to 
formulate them as oral dosage forms. These strategies include salt formation, 
microenvironmental pH control, solubilization with surfactants (3), complexation with 
cyclodextrins (CDs) (4), solid dispersions (5), lipid based formulations (6) and 
nanoparticle (NP) formulations (7). Besides the solubility, the pharmacokinetic and 
pharmacodynamic properties of pharmacologically active moieties can be changed by 
using novel drug delivery systems or by modifying the molecular structure and/or 
physiological parameters depending on the route of administration. The interaction 
between CD, drug and dosage form influences the kinetics of key processes of oral drug 
delivery, including dissolution and absorption (8,9). Thus, the choice of the best drug 
delivery system will aim to enhance drug bioavailabilty and reduce their toxicity. In the 
complexation processes the different interactions between chemistry species (molecules, 
ions, radicals) that do not involve covalent bonds are mostly of the host-guest type. CDs 
seem to be the most important ones in this domain. Also, the incorporation of CDs into 
a drug dosage form may affect the activity of basic pharmaceutical ingredients and may 
modify the properties of the whole drug formulation. Nearly 40 marketed commercial 
drug products currently benefited from such CD technology (10). The complexation can 
influence the drug release, but the process does not affect the drug intrinsic ability to 
permeate lipophilic biomembranes. However, CDs have been used as permeation 
enhancers in topical formulations (11) and to increase the permeability of water-
insoluble drugs by making the drug available at the biological membrane surface (skin, 
mucosa or the eye cornea). For water-soluble drugs CDs increase drug permeability by 
direct action on membrane and enhance drug absorption and/or bioavailability (12-19). 
The drug release can be modified by using CDs and their derivatives. Among the 
different CDs, for example the hydrophobic CD derivatives such as ethylated and 
peracylated ones have been employed as slow-release carriers for water-soluble drugs 
(20). In addition, the use of CDs in biological system often requires amphiphilic 
properties; thus, several modifications have been performed on CDs with the aim to 
provide versatile carriers and delivery systems for hydrophilic and hydrophobic drugs 
(21,22). Many studies have been developed where CDs are used as modified release 
carriers (eg., colon-specific delivery systems) (23-26). In the last two decades, synthetic 
macromolecules with functional groups of pharmacological potential have received 
considerable attention. CDs are potent candidates for such role through the formation of 
drug conjugates improving certain drug properties such as solubility and/or 
bioavailability (27). However, physic and pharmaceutical properties of CD conjugates 
in which a drug is covalently bonded to the CD may be significantly different from 
those of the inclusion complexes (28). The use of the CD conjugate-based repeated- and 
prolonged-release systems is described in various studies (13,29,30).  
 
 
Cyclodextrins 
 
Parent / Natural  
 
Naturally occurring CDs are obtained through the enzymatic reaction on the 
starch.  CDs are cyclic oligosaccharides built up from glucopyranose units linked by α-
1,4 bonds, thus forming a torus-like macro-rings. They are characterized as crystalline, 
homogeneous and non hygroscopic substances. The natural CDs are: αCD 
(Schardinger’s α-dextrin, cyclomaltohexaose, cyclohexaglucan, cyclohexaamylose, 
αCD, ACD, C6A) comprising six glucopyranose units; βCD (Schardinger’s β-dextrin, 
cyclomaltoheptaose, cycloheptaglucan, cycloheptaamylose, βCD, BCD, C7A) 
comprising seven of such units, and γCD (Schardinger’s γ-dextrin, cyclomaltooctaose, 
cyclooctaglucan, cyclooctaamylose, γCD, GCD, C8A) that comprises eight of such 
units (Fig. 1) (4,31,32). The most important characteristics of the natural CDs are 
summarized in Table 1 (4,31).  
The CDs may modify important properties of the drugs through their inclusion 
complex formation ability. For a long time only the parent (or major) CDs (α, β, and 
γCD) were known and well characterized. Subsequently other CDs have been 
discovered. CDs containing less than seven units cannot be formed due to steric 
hindrance while the homologues with nine or more glucose units are very difficult to 
purify (33,34). 
 
 
 
 
 
 
 
Fig. 1. Schematic cyclodextrins structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Derivatives 
 
In recent years, many CD derivatives have been synthesized. These derivatives 
usually are produced by aminations, esterifications, or etherifications of their primary 
and secondary hydroxyl groups. These CD derivatives and also CD polymers have been 
prepared to obtain better properties (i.e. better solubility, stability, and inclusion 
abilities) than those of the parent CDs (35,36). Depending on the substituent, the CD 
derivatives may change their hydrophobic cavity volume and also solubility, stability 
against light or oxygen, and help to control the chemical activity of guest molecules in 
comparison to their parent CDs. In the Table II, various CD derivatives are presented 
(30,37-39). Other type of CD derivatives - the amphiphilic ones - can be obtained by the 
introduction of long alkyl or fluoroalkyl chains at primary and/or secondary sides of the 
CDs. These CDs have shown the ability to form monolayers at the air-water interface 
and supramolecular structures, such as micelles or bilayer vesicles in water and NPs. In 
many cases, the CD cavities retain their full capacity to include external guests, showing 
promise for a possible application in drug delivery (21,40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table I. Characteristics of α, β, and γCD  
 
   
 α β γ 
Nº of glucose units 6 7 8 
Mol weight 972 1135 1297 
Solubility in water (g/100ml), room T 14.5 1.85 23.2 
[R]D25 ºC 150.0 ± 0.5 162.5 ± 0.5 177.4 ± 0.5 
Cavity diameter (Å) 4.7-5.3 6.0-6.5 7.5-8.3 
Height of torus (Å) 7.9 ± 0.1 7.9 ± 0.1 7.9 ± 0.1 
Diameter of outer periphery (Å) 14.6 ± 0.4 15.4 ± 0.4 17.5 ± 0.4 
Approx. cavity volume (Å3) 174 262 427 
Approx. cavity volume in 1 mol CD (ml) 104 157 256 
Approx. cavity volume in 1 g CD (ml) 0.10 0.14 0.20 
Crystaline forms (from water) Hexagonal plates Monoclinic parallelograms 
Quadratic 
prisms 
Crystal water, wt% 10.2 13.2-14.5 8.13-17.7 
Diffusion constant at 40 ºC 3.443 3.224 3.000 
Hydrolysis by A. oryzae α-amylase Negligible Slow Rapid 
Vmax value, min-1 5.8 166 2300 
Relative permittivity at pH 5.3, 25 ºC (on incorporating the 
toluidinyl group of 6-p-toluidynilnaphthalene 2-sulphonate)  47.5 52.0 70.0 
(on incorporating the naphthalene group) a 29.5 39.5 
pK (by potentiometry) at 25 ºC 12.332 12.202 12.081 
Partial molar volumes in solution (ml/mol) 611.4 703.8 801.2 
Adiabatic compressibility in aqueous solutions ml (mol-1 bar-1) x 104 7.2 0.4 -5.0 
a
 Naphthalene group is too bulky for the αCD cavity 
  
Table II. Cyclodextrins Derivatives and Their Release Behavior 
 
Hydrophilic derivatives   
   Methylated β-Cyclodextrin   
            methyl-β-cyclodextrin MeβCD  
            randomly methylated-β-cyclodextrin RMβCD (RAMEB)  
            dimethyl-β-cyclodextrin DMβCD (DIMEB)  
            randomly dimethylated-β-cyclodextrin RDMβCD  
            trimethyl-β-cyclodextrin TMβCD                    Immediate release 
            acetylated dimethyl-β-cyclodextrin DMAβCD  
   Hydroxyalkylated β-Cyclodextrin  Enhanced dissolution and absorption 
of poorly water-soluble drugs             2-hydroxyethyl-β-cyclodextrin 2-HEβCD 
            2-hydroxypropyl-β-cyclodextrin 2-HPβCD  
            3-hydroxypropyl-β-cyclodextrin 3-HPβCD  
            hydroxybutenyl-β-cyclodextrin  HBenβCD  
            2,3-dihydroxypropyl-β-cyclodextrin 2,3-DHPβCD  
   Branched β-Cyclodextrin   
           glucosyl-β-cyclodextrin G1βCD  
           maltosyl-β-cyclodextrin G2βCD  
           glucuronyl-glucosyl-β-cyclodextrin GUGβCD  
   
Hydrophobic derivatives   
   Alkylated β-Cyclodextrin   
             2,6-di-O-ethyl-β-cyclodextrin DEβCD  
             2,3,6-tri-O-ethyl-β-cyclodextrin TEβCD  
   Acylated β-Cyclodextrin  Prolonged release 
           2,3,6-tri-O-acyl(C2-C18)-β-cyclodextrin TAβCD  
           2,3,6-tri-O-butanoyl-β-cyclodextrin TBβCD Sustained release of water-soluble 
drugs            2,3,6-tri-O-valeryl-β-cyclodextrin TVβCD 
           2,3,6-tri-O-octyl-β-cyclodextrin TOβCD 
   
Ionizable derivatives   
   Anionic β-Cyclodextrin   
          O-carboxymethyl-O-ethyl-β-cyclodextrin CMEβCD Delayed release (pH-dependent 
release) 
   
          β-cyclodextrin sulfate βCD sulfate  
          sulfobutyl ether group-β-cyclodextrin (d.s.4) SBE4βCD  Immediate release 
          sulfobutyl ether group-β-cyclodextrin (d.s.7) SBE7βCD  
   
   Cationic β-Cyclodextrin  Prolonged release 
          tri-methyl-ammonium-β-cyclodextrin TMAβCD  
   
Drug-CD conjugate  Delayed release (site-specific release) 
d.s. = degree of substitution   
 
Complexation 
 
In an aqueous solution, the slightly apolar CD cavity is occupied by water 
molecules of high enthalpy (polar-apolar interaction). These water molecules can be 
readily substituted by appropriate “guest molecules” which are less polar than them 
(Fig. 2). The complexation process is most frequently a 1:1 host:guest ratio, however 
2:1, 1:2, 2:2, or even more complicated associations, and higher order equilibrium 
exists, almost always simultaneously (4). 
 
 
 Fig. 2. The interaction of a drug with a cyclodextrin to form an inclusion complex 
 
Applications 
 
The most interesting property of CDs is their ability to form inclusion complexes 
with a large variety of apolar and hydrophobic molecules. In some cases, only a portion 
of the molecule is included (4). CDs have been used in pharmaceutical formulations in 
order to enhance the solubility, dissolution rate, stability, bioavailability, and oral 
absorption or to modulate biological activity of drugs (41-43). In addition, CDs have 
been also used to reduce or prevent GI and ocular irritation, to reduce or eliminate 
unpleasant smells or tastes, to prevent drug-drug or drug-additive interactions, or to 
convert oil and liquid drugs into microcrystalline or amorphous powders (8,44). 
Moreover, these substances are also used to modify the drug release from different 
systems: The hydrophilic CD derivatives such as 2-HPβCD and SBEβCD are used for 
improving solubility and dissolution rate of poorly water-soluble drugs (45), while 
hydrophobic CD derivatives such as ethylated and acylated CD are used as slow-release 
carriers for water-soluble drugs (46). Furthermore, advanced controlled-release profiles 
can be achieved by a combination of CD derivatives and pharmaceutical additives (47). 
It is noteworthy that the CDs toxic effects can be minimized by appropriate choice of 
the CD or its derivative to the administration route (4,31). 
 
Release behavior 
 
For better understanding, the drugs release behavior is convenient considering 
the Biopharmaceutics Classification System (BCS) that is divided into four classes 
regarding the expectations on the in vitro-in vivo correlations: class 1 - high solubility-
high permeability, class 2 - low solubility-high permeability, class 3 - high solubility-
low permeability, class 4 - low solubility-low permeability (48,49).  
The relative contribution of the different mechanisms involved in the drug 
release leads to a change in their dissolution profiles. The influence of CDs derivatives 
on the drug release place and/or time profile is presented in Table II (24). Some selected 
studies where the CDs have been used to modify the release of drugs will be presented 
below. 
 
Immediate release 
 
All drugs that have poorly water solubility (classes 2 and 4) may improve this 
property through complexation with hydrophilic CDs or their derivatives and 
consequently their dissolution rate enhancement. Several examples are shown in the 
Table III. Thus, the inclusion complexes can be used for immediate release applications 
allowing the drug to dissolve in the GI contents, without delaying or prolonging the 
dissolution or absorption of drugs (24,50).  
Table III. Examples of the Increase the Solubility by the use of Cyclodextrins and Their Derivatives 
 
Ciclodextrin Drug Therapeutic 
group 
Other enhanced 
effect 
Observation (Ref) 
HPβCD Alkannin/shikoni
n enantiomer Antioxidant 
in vitro 
permeability, 
photostability 
(113) 
βCDs and 
derivatives Naringenin Antioxidant 
 Combined with pH variation                   (114) 
γCD > 
αCD and βCD 
Coenzyme Q10 
(CoQ10) 
Antioxidant  Higher Cmax and AUC in adult male and female                                                      (115) 
βCD < 
HPβCD Resveratrol Antioxidant 
 Antioxidant activity in free form has little 
difference with Res in complexed form  (116)                                    
HPβCD, βCD dl-alpha-tocopheryl acetate antioxidant 
Water 
penetration, 
wettability 
HPβCD 
βCD does not solubilize the drug; 
drug-HPβCD at 1 : 2 molar ratio             (117) 
HEβCDs, 
HPβCDs Naproxen  NSAID 
 βCD derivative in the 1:1 molar ratio; 
similar solubilising effect                       (118) 
βCD, 
MeβCD 
Ketoprofen 
Ibuprofen  
Naproxen  
NSAIDs 
 MeβCD is the most effective amorphizing 
agent for ibuprofen and ketoprofen; 
ibuprofen shows comparable dissolution rates 
from IB-βCD and IB-MeβCD                 (119)                 
MeβCD Ibuprofen NSAID Improved 
wettability 
Complex increased dissolution rate was 
attributed to its amorphous nature           (120)                                
αCD, 
βCD, 
γCD 
Meloxicam  NSAID 
 Drug hydrophilicity may be due either to the 
formation of inclusion complexes or to a 
highly homogeneous assembly between the 
CD and the drug in the solid state           (121)                                                                                 
SBEβCD, 
TMAβCD, 
βCD, MeβCD 
Naproxen NSAID 
 All SBEβCD products exhibited significantly 
better dissolution properties than the 
TMAβCD corresponding ones                (38) 
βCD RS(±) Ibuprofen NSAID 
Bioavailability 
increase and 
minimizing the 
drug dose  
Dissolution rate coefficient and the dissolved 
amount of the complex after 75 min was 
higher than that of unprocessed drug and of 
its untreated physical mixture                  (122) 
SBE7βCD, 
βCD Ketoprofen NSAID 
 SBE7βCD is more effective solubilising agent 
for drug than βCD                                    (123) 
βCD 
MeβCD Ketoprofen NSAID 
 Synergistic effect by combined use of 
phospholipids and CDs                            (124) 
βCD  
γCD Ppiroxicam  NSAID 
 Complex was found to be significantly higher 
than that of the physical mixture             (125) 
βCD Ibuprofen Indomethacin  NSAIDs 
 Water amount is not important to obtain 
complexes if the drug intrinsic solubility is 
not modified by complex formation         (126)                            
βCD Meloxicam NSAID  NaOH was employed to increase βCD 
solubility to achieve uniform coating      (127)                                                 
βCD Ketoconazol  Antifungal 
 No differences between binary and 
multicomponent complexes from the same 
molar ratio (1:2) at pH 5; at pH 6, inclusion 
complex formed in presence of HCl lead to 
higher drug solubility      (128) 
βCD and its 
amorphous, 
MeβCD 
Econazole  Antifungal 
 MeβCD complexes exhibited better 
performance than those with βCD         (129) 
 HPβCD Itraconazole  Antifungal  (130) 
 
 
 Continuation Table III 
 
Ciclodextrin Drug Therapeutic 
group 
Other enhanced 
effect 
Observation (Ref) 
βCD Oxazepam Benzodiazepine  (131) 
βCD, HPβCD Bromazepam  Benzodiazepine                                                                      (132) 
SBEβCDs Danazol  Steroid  SBEβCDs (with different d.s.)                   (133)                                 
HPβCD 
(SBE)7mβCD Phenytoin Antiepileptic 
 
 (134) 
HPβCD, 
MeβCD, 
HPγCD 
Phenytoin Antiepileptic 
 
 (135) 
HPβCD Bropirimine Antiepileptic Bioavailability improved  (136) 
βCD Atenolol Antiepileptic  (137) 
HPβCD Oxcarbazepine Antiepileptic  Blend of HPβCD with NaCMC                  (138) 
DMβCD Paclitaxel Anticancer  The mostly effective was 2.3mM in a 0.1M 2,6-DMβCD aqueous solution                          (139) 
βCD,  
γCD Artemisinin Anti-parasites 
 Drug higher rate and extent of absorption 
compared to reference preparation using 12 
healthy human volunteers                           (140)                             
αCD, βCD 
γCD, HPβCD, 
SBEβCD, 
DMβCD, 
PMβCD, 
G1βCD, 
G2βCD 
Artemisinin Anti-parasites  
α<γ≤βCD 
G2βCD≈G1βCD≈PMβCDb≈βCD<HPβCD< 
SBE7βCD<DMβCD most effective CD was 
DMβCD 
                                                                    (141) 
βCD Carvedilol Beta blocker  (142) 
βCD Warfarin Anticoagulant  Preparation method and pH influence the βCD 
ability to include the drug                           (143)                                             
βCD, 
HPβCD Theophylline 
Respiratory 
diseases 
 HPβCD doesn’t influence drug solubility 
probably due to the bulky OH groups        (144)            
HBenβCD Saquinavir Antiretroviral in HIV therapy 
Enhance the 
bioavailability  (39) 
βCD, HPβCD, 
DMβCD Tadalafil 
Erectile 
dysfunction 
 Drug dissolution was markedly enhanced 
(>75% in the first 5 min)                            (145)                                       
αCD,  βCD, 
γCD, HPβCD, 
DMβCD, 
TMβCD 
Azadirachtin 
Anti-malarial, 
Anti-tuberculosis, 
Anti-worms, 
Antifungal 
High bioactivity 
low toxicity Herbal medicine/healthcare products         (146) 
βCD,  
HPβCD Rhein 
Antiviral, 
anticancer 
 
 (147) 
HPβCD Celecoxib  Anticoagulan 
 Evaluation of the effect of hydrophilic 
polymers on the complexation and solubilizing 
efficiencies of HPβCD                                (148) 
HPβCD 
SBEβCD XK469
a PPA Anticancer 
 Synergistic effect of pH adjustment with 
cosolvency, micellization, or complexation                       
                                                                    (149) 
HPβCD Sulfisoxazole Antibacterial 
 Solubilization can be improved by addition of 
the triethanolamine to the complexation 
medium or by ionization of the drug through 
pH adjustments                                           (150) 
HPβCD Tanshinone IIA 
Antibacterial, 
antitumor, 
anti-inflammatory 
In vitro permeability 
 
                                                                      (18) 
2-Phenoxy-propanoic acid 
a 2-[4-[(7-Cloro-2-quinoxalinyl)oxy]phenoxy]propanoic acid 
b
 2,3,6-Partially methylated-βCD 
Modified release 
  
This term is defined in the Eur. Pharm. (51) as a modification of the rate or place 
at which the active substance is released. Modified release products cover a wide range 
of release models, the principal types of which would include “delayed-release” and 
“prolonged-release” products.  
 
Prolonged release 
 
Most of the slow-release preparations have been aimed at achieving zero-order 
or pH-independent release of drugs to provide a constant blood level for a long period 
of time; this kind of formulation has many advantages, such as reducing the frequency 
of dosing, prolonging the drug’s efficacy and avoiding the toxicity associated with the 
administration of a simple plain tablet; for this purpose, hydrophobic CDs, such as 
alkylated and acylated derivatives, are useful as slow-release carriers for water-soluble 
drugs (classes 1 and 3) (22,24,50,52).  
 
Conventional. It was shown that the freeze-drying method is simple and suitable 
for obtaining an inclusion complex of salbutamol with βCD and ethylated-βCD (Et-
βCD). The different sustained-release behaviors obtained suggest that both the solubility 
and the dissociation of the complexes are responsible for the dissolution rates of the 
drug. The results indicate that Et-βCD may be considered as a good carrier for the 
sustained release of salbutamol (53).  
The pharmaceutical application of triacetyl-βCD (TAβCD) as a slow release 
carrier for flufenamic acid (FA) was evaluated. An initial high-plasma peak 
concentration does not occur after the administration of FATAβCD complexes when 
compared with other excipients. The FATAβCD complex used appears to be 
appropriate for practical clinical applications that would result in reduced side effects of 
the drug and prolonged action (20).  
The combination of hydrophilic CDs such as HPβCD and hydrophobic CDs such 
as perbutanoyl-βCD (TBβCD) has been analyzed as controlled-release systems for 
extremely hydrophilic drugs (captopril, Cap). The binary system of CapHPβCD or 
CapTBβCD and the ternary system of CapTBβCD/HPβCD were prepared. The release 
rate of drug from the binary HPβCD system was rather fast, whereas that from the 
binary TBβCD system was comparatively slower. The retarding effect was dependent 
on the amount of hydrophobic CD and was attributable to a gel formation of HPβCD in 
the TBβCD hydrophobic matrix. During this period, a viscous gel layer of the 
hydrophilic CD gradually forms on the surfaces or inside the tablets, and at a later stage 
of the release, the drug or the complex may be released through diffusion of the gel 
layer. This release rate can be controlled by adjusting the relative molar ratio of both 
components (54).  
The controlled-release of metoprolol (Met), a water-soluble β1-selective 
adrenoreceptor antagonist, by means of a combination of HPβCD and a hydrophobic 
polymer, ethylcellulose (EC) was reported. The release rate of Met is HPβCD amount 
dependent, when formulated as complexes in the EC tables, i.e., the release rate 
decreased when appropriate amounts of HPβCD were added to hydrophobic EC matrix. 
This rate decrease may be attributable to a gel formation at high concentrations of 
HPβCD. HPβCD is widely used as a solubilizer and a fast-dissolving carrier for poorly 
water soluble drugs. However, the present study showed that it may work as a retarding 
carrier for the release control of water-soluble drugs such as Met (55).  
Fernandes et al. studied the nicardipine release rate using hydrophilic (HPβCD) 
and hydrophobic (TAβCD) complexes. They observed that required sustained period 
could be controlled by adjusting the mixing ratio of its complexes, pointing out the 
importance of the carrier choice. This study showed that both CDs inclusion complexes 
achieved prolonged action, improved bioavailability, and reduced side effects after oral 
administration in rabbits (25). 
The piroxicam (PX) following complexation with HPβCD was used to develop a 
controlled-release formulation for buccal administration. Matrix tablets containing the 
PXHPβCD complex and swellable hydrophilic polymers, such as hydroxypropylmethyl 
cellulose (HPMC) and Carbopol (C940), were prepared. Their release profiles were 
evaluated and showed the faster PX release (in vitro) when compared to those 
containing a physical mixture or “free” drug. The PX behavior from the polymer 
matrices in a constant mode over the passage of time was characterized by prolonged 
effect. The differences observed in release rates of PX from the all tablets could be 
attributed to the presence of the polymers and inclusion complexes (56).  
The CD was also studied in relation to its relative contribution in the different 
mechanisms involved in the drug release from tablets produced with a wide range of 
HPMC proportions. The results showed that the βCD and HPβCD strongly determine 
the dissolution rate of drugs due to inclusion complexes formation. For some HPMC 
and drug ratios was observed that low CD concentrations promote drug diffusion due to 
the decrease on drug interactions with the polymer, while the opposite effect was 
observed for high CD concentrations (free CDs increase the tortuosity of the diffusional 
path). CD solubilising capacity plays an important effect on hydrophobic 
sulphamethizol release profile, where the release rate was greater for HPMC matrix 
tablets containing CDs. In contrast, the delay in the hydrophilic diclofenac (Dic) release 
profile may be attributed to the hindering effect of free CDs on drug diffusivity. The 
simplex centroid design used to prepare the tablets allowed to obtain the second-order 
canonical equations, which are particularly useful to predict the release behavior of 
tablets containing mixtures of HPMC, CD, and lactose (57).  
Dic, as poorly soluble-free acid (DicH) or freely water-soluble sodium salt 
(DicNa), was analyzed following addition of the hydrophilic CD (HPβCD) in erodible 
hydrophilic poly(ethyleneoxide) matrices. This study, intended for oral drug delivery, 
has demonstrated that this incorporation affects drug release behavior and transport 
properties through artificial and biological membranes. Their modulator effect is 
observed not only on drug dissolution rate but also on environment where drug release 
occurs (aqueous medium, membrane interface) (58).  
The behavior of the vinpocetine (VP), a poorly soluble base-type drug, following 
multicomponent complexation (MCC) with βCD, SBEβCD, tartaric acid (TA), PVP, 
and HPMC, on the design of controlled-release hydrophilic HPMC tablets was 
evaluated. The in vitro release profiles were carried out by a pH gradient method. The 
addition of βCD and SBEβCD, either in MCC or as physical mixture forms, improved 
the VP release profiles as a consequence of VP complexation, and the tablet 
formulations with VPSBEβCD-TA and VPβCD-TA MCC showed some variation on 
the rate and extent of VP dissolved as a result of different solubility performances of 
both CDs (59). 
Hydrogels of different CDs cross linked with ethylene glycol diglycidyl ether 
(EGDE) were prepared. Estradiol presented a higher affinity for βCD, MβCD, and 
SBβCD than for HPβCD. The affinity for this last CD was greatly enhanced when 
HPMC (0.25%) was added to the medium and the system was autoclaved. The 
application of a one-step cross-linking with EGDE, under mild conditions, enabled the 
formation of MβCD and HPβCD hydrogels. By contrast, the low solubility of βCD and 
the high anionic character of SBβCD hindered obtaining hydrogels. The estradiol 
loading was driven by the interaction of the drug with the CD network. The high 
loading ability of the hydrogels may enable the incorporation of a therapeutic dose of 
estradiol in a small piece of hydrogel, being the release sustained for several days owing 
to the affinity of the CD for the drug (60). 
In other study with hydrogels consisting of polyvinylpyrrolidone/polyethylene 
glycol dimethacrylate (PVP/PEG-DMA), the CDs were grafted to the polymer matrix in 
4-5 % (w/w) in an attempt to retard the release of water-soluble drugs. Vinyl derivatives 
of α, β and γCD were produced, added to the prepolymer blend, and cured by UV light. 
During this curing process, the CD derivatives were covalently incorporated into the 
hydrogel matrix, which was loaded with ibuprofen by swelling. The release of the 
model drug from CD modified hydrogels shows that especially covalently bonded βCD 
can change both the release rate and the release profile of ibuprofen (61). 
The interactions between meglumine antimoniate (MA) and βCD induced by 
heating and freeze-drying were investigated, and their impact on antimony (Sb) 
absorption, administered by oral route, was evaluated. As a consequence of the slow 
drug release property of MAβCD nanoassemblies (sustained-release system of MA), 
following dilution in water, one can expect a change of the drug absorption site in the 
GI tract, when compared to MA alone or to the heated MAβCD physical mixture (62). 
The combination of the metformin hydrochloride (MH) with a hydrophobic CD 
(TAβCD) and its dispersions in a suitable polymeric matrix (i.e., HPMC, xanthan gum, 
chitosan, EC, EudragitL100-55, Precirol), varying the relative amounts of MHTAβCD, 
was effective in adequately modulating the drug release rates. The matrix-tablet 
formulation containing the 1:1 (w/w) blend of MHTAβCD as co-ground and spray-dried 
systems fully achieved the prefixed goal. The results showed about 30% released drug 
after 2 h at gastric pH and overcoming 90% released drug within the subsequent 3 h in 
jejunal fluid (9). 
 
Floating. The enhancement of the furosemide (FR) bioavailability by prolonging 
its duration in the stomach via the floating dosage forms with controlled release was 
evaluated. In this study, the floating dosage forms (bilayer floating tablets) with 
controlled release were prepared using solid dispersions of FR with βCD in a 1:1 
proportion, and both in vivo and in vitro results were studied. The results show that the 
bioavailability of FR was excessively increased compared to conventional forms and 
that absorption of FR taken place vastly in stomach and upper part of small intestine 
(63).  
The floating tablets of curcuminβCD (CURβCD) complex were formulated to 
provide sustained release of drug with an aim to provide an effective therapy with 
enhanced solubility and bioavailability, targeted action, and better absorption to treat 
stomach cancer. The formulation CURβCD complex exhibited maximum sustained 
release of curcumin with excellent floating and swelling properties. Also, in vivo 
antitumor studies confirmed that the overall rate of tumor incidence and number of 
tumors/mouse is less in animal group treated with CURβCD complex compared to 
animals treated with CUR and CURβCD (control II) (64). 
The gastroretentive floating effervescent and non-effervescent tablets of 
silymarin (flavonolignans) were analyzed with purpose to increase the efficacy and 
stability of the drug in the stomach. The short half-life of the silymarin, poor 
bioavailability, and faster solubility in acidic medium make it a suitable candidate for 
gastroretentive drug delivery system. It was concluded that HPMC in combination with 
crospovidone and microcrystalline cellulose can be promising polymers for effervescent 
gastroretentive drug delivery system. Swelling studies indicate significant water uptake 
and contributed to drug release and could be significant in gastric retention. On the 
other case, non-effervescent floating formulations based on polypropylene foam powder 
studied for their ability to control drug release over prolonged period of time. The drug 
release pattern can effectively be adjusted by varying formulation parameters such as 
concentration of swelling agent and βCD, type of matrix forming polymers, and blend 
of matrix forming polymers. The developed floating tablets of silymarin may be used 
for prolonged drug release, thereby improving the bioavailability and patient 
compliance (65).  
 
Mucoadhesive. The interactions between a cationic polymer hexadimethrine 
bromide (HDMBr) and an anionic CD, SBEβCD, were investigated, as well as the 
potential of such a system for mucoadhesive, sustained drug delivery. The results show 
that interactions between the anionic SBEβCD and the cationic HDMBr can be used to 
obtain mucoadhesive sustained drug delivery system under certain conditions. 
Triclosan/SBEβCD/ HDMBr complex is better retained on a cation-exchange media 
than the triclosan/HPβCD/HDMBr complex. The positive charge of HDMBr did not 
have the expected effect on the buccal mucosa. Thus, was concluded that although a 
positive charge is likely to promote mucoadhesion, other polymers attributes, such as 
molecular weight and viscosity, may have equally beneficial effects (66). 
In the continuing challenge to improve the properties of delivery systems, the 
possibility to modify chitosan by introducing βCD was analyzed, and then the 
mucoadhesive properties of this synthesized CD polymer were investigated. The use of 
βCD in combination with chitosan resulted in a polymer which showed substantial 
mucoadhesive properties, although lower compared to that of chitosan alone. The 
molecular size of CD-chitosan might lead to a decrease of the interpenetration into the 
mucus layer with a subsequent decrease in mucoadhesivity. In fact, it is known that, 
besides molecular weight, mobility and flexibility of polymeric chains play an 
important role in mucoadhesion. A monosubstituted βCD derivative could be efficiently 
grafted on chitosan, yielding a CD polymer with promising inclusion and mucoadhesive 
properties (67). 
In another study, a novel thiolated carboxymethyl chitosan-g-β-cyclodextrin 
(CMC-g-βCD) was synthesized and characterized as mucoadhesive drug carrier. For the 
drug delivery study, tablets were prepared and the transfection of the hydrophobic 
model drug, ketoprofen (KP), was investigated as well as the swelling and 
mucoadhesive properties of the compacts. The swelling may have contributed to the 
mucoadhesiveness of the thiolated polymers. The KP release results indicate that this 
system seems to be a very promising vehicle for the administration of controlled release 
of hydrophobic drugs. The ability of βCD present in the thiolated polymers to form 
host–guest inclusion complexes with the drug molecules and disulfide cross-linking 
between the polymer chains could be the main reasons for the slow and steady drug 
release from thiolated CMC-g-βCD tablets. Perhaps the release of drug may be 
controlled by swelling followed by a diffusion-controlled mechanism (68). 
Other formulations, aimed for buccal delivery, involving binary products containing 
bupivacaine hydrochloride (BVP HCl), an amide-type local anesthetic, with parent βCD 
and its soluble epichlorohydrin-βCD polymer (EPI-βCD) were prepared and evaluated 
as a novel mucoadhesive system. It was possible to properly tailor the drug release rate 
according to the desired effect, i.e., a rapid onset of anesthetic action for simple dental 
procedures or a prolonged effect in post surgical procedures or in the treatment of oral 
mucositis. The inclusion complex with βCD reduced the drug dissolution rate, while the 
complexation of BVP HCl with EPI-βCD increased the drug dissolution rate (69). 
The effect of flufenamic acid (FLU) complexation with HPβCD on its 
dissolution properties and release rate from buccal film formulations was investigated, 
with the objective of improving the therapeutic efficacy. Chitosan, a natural cationic 
polysaccharide consisting in a copolymer of N-acetyl-D-glucosamine and D-
glucosamine, was selected as the mucoadhesive polymer for the development of the 
buccal film formulation. Moreover, it was demonstrated that CD complexation could be 
a suitable strategy to optimise the drug release feature from the system. In fact, 
introduction of drug as complex with HPβCD enabled a clear improvement of drug 
release with respect to the film containing the plain drug, allowing achievement of 
complete release within 4-5 h, which is considered the usual maximum duration for 
buccal drug delivery. The main advantage expected from this formulation in comparison 
with traditional oral therapy is the reduction of drug dose because its direct localization 
in the inflammation site, with the consequent minimization of potential systemic side 
effects. Future in vivo studies on human voluntaries are planned to evaluate the actual 
therapeutic effectiveness of the developed film formulation of FLU, and the effect of 
different drug loads will be studied (70). 
 
Osmotic pump - Stella et al. (71-76) developed various studies involving 
osmotic pump tablets (OPT) and SBEβCD which are described below. 
The effect of SBEβCD on the release of poorly water-soluble drugs (testosterone) from 
therapeutic systems (controlled porosity osmotic pump tablets) showed that CD 
derivative was capable of increasing the solubility and enhancing the release of the 
steroid. Moreover, it was proposed that current tablets containing SBEβCD (due to its 
seven negative charges and seven sodium ions per molecule, in average) may also 
exhibit osmotically controlled release-properties for drugs (71). 
The factors responsible for controlling drug release of the chlorpromazine 
through the porous membrane were evaluated from release studies. The results suggest 
that the membrane factors responsible for drug release from OPTs containing cores 
utilizing SBE7mβCD, as both a solubilizing and osmotic agent, are the amount of 
micronized lactose and triethyl citrate (TEC), the size of micronized lactose, and the 
type of plasticizer in the membrane. Moreover, it was also confirmed that the pores in 
the OPT membranes are formed by leaching micronized lactose into the dissolution 
medium and by a decreasing plasticizer effect observed with decreasing amounts of 
TEC. In addition, the change in membrane pores which resulted from all these factors 
was well indicated by the total membrane surface area per unit weight after the release 
studies and by the mechanical permeability of the membranes (72). 
The osmolality of HP and SBECD solutions over the large concentration range 
relevant to tablet formulations was measured, and a model capable of describing the 
osmolality generated in CD solutions as a function of concentration was developed. 
This study was conducted in water with eight CDs: HPβCD, HPyCD, SBE4mβCD, 
SBE7mβCD, SBE9mβCD, SBE4myCD, SBE9myCD, and SBE12myCD. Both HPCDs had a 
total degree of substitution (TDS) of four, and the TDS in the SBECD nomenclature 
was indicated by the number in subscript, followed by the letter “m” indicating that 
these materials were composed of mixtures of (SBE)CDs of various degrees of 
substitution. As expected, it showed that osmolality was directly dependent on the 
number of particles in solution. This term may be related to the effect of the solute 
addition on water structure and could be considered as an indicator of the amplitude of 
deviation from ideality. The unified empirical model applied in this study of the osmotic 
properties of CDs for use in osmotic pump tablets; it is reasonably for predicted the 
osmolality of the HP and SBECD solutions solely based on solution concentration and 
TDS (73). 
The role of the SBE7mβCD-to-drug ratio in the OPT core with seven model 
drugs, including both highly and poorly water-soluble drugs, was studied. SBE7mβCD 
serves as both a solubility modulator and as an osmotic pumping agent for OPTs, from 
which the release rate of both water-soluble and poorly water-soluble drugs can be 
controlled. An appropriate composition ratio was determined for SBE7mβCD to drug 
(those requiring solubility enhancement) for complete release of drugs over 12 h from 
the OPTs. For soluble drugs, SBE7mβCD acts primarily as an osmotic and an OPT 
control agent. Significantly, SBE7mβCD not only enhances the delivery of poorly 
soluble drugs from OPTs but acts as a controlling excipient for soluble drugs such that 
the release rate, corrected for tablet surface area, of both poorly soluble and soluble 
drugs are similar (74). 
A controlled porosity-osmotic pump pellets (CP-OPP) using SBE7mβCD as a 
solubilizing and osmotic agent and prednisolone (PDL) as drug was prepared in order to 
deliver a sparingly water-soluble drug, in a controlled-release fashion. The evaluation of 
this system includes the factors influencing drug release and the probable mechanisms 
of drug release. The incorporation of SBE7mβCD significantly improves the solubility 
and thus the release of PDL through preformed as well as in situ complex formation. 
The pellet performance can be fabricated to achieve a desired release rate by modifying 
the molar ratio of SBE7mβCD to PDL, thickness of the microporous coating, and coating 
composition (e.g., polymer or pore former). In addition, a significant change in the drug 
release rate with a change in the osmotic pressure difference across the membrane 
indicates that osmotic pumping may be part of the mechanism of drug release from 
pellet formulations (75). 
The release mechanisms from the CP–OPPs containing precomplexed PDL were 
investigated. The PDL or CD release rate follows zero-order kinetics for up to 30–40% 
of drug release during the first 1–2 h and nonzero-order kinetics thereafter. The initial 
zero-order drug release is attributed to the constant driving forces mainly caused by the 
approximately constant concentration of CD with time. In contrast, the nonzero order 
drug release is associated with the combination of more significant diffusion with time 
as well as the change in concentration of CD resulting in changes in viscosity, 
diffusivity, and osmotic pressure in the pellet with time (76).  
  
Others. The incorporation of the physical mixtures of SBE7mβCD and a 
sparingly water-soluble drug into hydrophilic matrices to provide controlled and 
complete in vitro release, as well as the mechanisms by which SBE7mβCD increases the 
drug release from HPMC matrix tablets, was investigated. The in situ inclusion complex 
formation is the main mechanism by which SBE7mβCD improves the drug release rate. 
Higher medium penetration rate into the SBE7mβCD-containing matrices may also 
contribute to the improved release rate and is dependent on the ratio of solubility to drug 
load, on the molar ratio of SBE7mβCD to drug and not the absolute amount of 
SBE7mβCD (77). 
In another work, the HPβCD was used to evaluate its potential to control 
zolpidem (ZP) release (prolonged-release system) from zolpidem-loaded poly(dl-
lactide) or poly(dl-lactide-co-glycolide) microparticles. The release profiles of ZP from 
these systems showed an initial burst effect, and a subsequent slow ZP release was 
analyzed (78). 
The potential of SBE7βCD together with HPMC or PVP to solubilize and deliver 
the carbamazepine (CAR) (poorly soluble model drug) from sustained release (SR) 
beads was analyzed. SBE7βCD increases the aqueous solubility of CAR as well as 
HPMC, but not PVP. HPMC acts both alone and synergistically with SBE7βCD. Within 
a SR bead, SBE7βCD increases the CAR release rate, potentially by enhancing 
solubility and hence diffusion, while also increasing the osmotic drives through the 
aqueous ethylcelulose dispersions (Surelease® aqueous pores). The addition of HPMC 
does not improve the rate of CAR release, but does reduce the ratio of SBE7βCD needed 
to deliver CAR and therefore has potential advantages over the binary system. Both 
binary and ternary approaches are considered as suitable techniques to potentially 
improve the delivery and in vivo bioavailability of poorly soluble drugs, which have 
previously exhibited slow or incomplete release from SR beads (79). 
The γCD derivatives (variation on the alkyl chain length of γCD alkylcarbonates) 
complexation properties were analyzed, and it was shown that these CDs can improve 
both the solubility and the release rate of poorly water-soluble drugs. Also it was 
observed that the combination of various ratios of different alkylcarbonate complexes in 
a pharmaceutical formulation could enable drug release to be modulated (80). 
An innovative particulate system, called “beads” composed of αCD and 
vegetable oil, safe substances for oral administration, was proposed. The drug used was 
isotretinoin, a lipophilic molecule, sensitive to heat, oxygen and light, which was 
encapsulated in those beads. The results showed that αCD/oil beads were able to 
efficiently encapsulate and facilitate oral delivery of the drug (81). 
The possibility of controlling the release rate of simvastatin (SVA) from 
SVA/βCD coatings with different pH values was investigated. Results showed that the 
lower the pH value of the solution, the lower were the release kinetics of SVA, 
indicating that the release character of SVA could be controlled by adjusting the pH 
value (82). 
  In another study, it was assessed whether oral administration of the ethinyl 
estradiol (EE)βCD clathrate/ drospirenone (drsp) formulation affects the bioavailability 
and pharmacokinetics of EE and drsp. The results showed the relative bioavailability of 
EE and drsp after the administration of EEβCD clathrate/drsp was comparable with that 
achieved with EE/drsp or a reference suspension. Therefore, complete in vivo release of 
EE and drsp was achieved in healthy postmenopausal women following oral 
administration of EEβCD  clathrate/ drsp tablets. A βCD clathrate formulation of EE, 
when combined with drsp, did not influence the relative bioavailability of EE or drsp, or 
alter the pharmacokinetic profile of these hormones (83). 
The potential of βCD to control drug release from 
poly[methylenebis(acrylamide)aminoethylpiperazine] (HPMA) was investigated and the 
in vitro release behavior of anticancer chlorambucil (CLB) from these hyperbranched 
drug carriers was studied. The βCD introduction into HPMA showed that the initial 
burst release was slowed down. Furthermore, the release rate of CLB from HPMA-
βCDs increased with decreasing βCD content, and the corresponding cumulative 
amounts of CLB released were between 42.3% and 66.0% for 10 h. This result indicates 
that the CLB release from the HPMA-βCDs is a function of βCD content and the 
presence of βCD in HPMA retarded the CLB release rate. Thus, the controlled release 
experiments showed that the presence of βCD can appropriately slow CLB release from 
HPMA-βCDs and adjust the ratio of CLB released in relation to the total drug load (84). 
Highly structured and porous poly(methyl methacrylate) PMMA membranes 
functionalized with HPβCDs, impregnated with ibuprofen using scCO2 in batch mode, 
were tested as controlled drug delivery devices by in vitro tests into buffer solution at 
pH 7.4, and the drug release data was modeled using a mathematical theory based on 
Fick’s second law of diffusion. The introduction of CDs physically entrapped in the 
PMMA matrix leads to an increase of drug release to the buffer solution at pH 7.4 when 
compared to the neat PMMA membrane. The supercritical fluid-assisted membrane 
formation is a greener alternative to produce porous polymeric matrixes containing 
CDs, with improved characteristics such as enhanced drug loading, controlled drug 
release ability, which might have promising biomedical applications (85).  
 
Delayed release 
 
An enteric preparation can be classified as time-controlled release, since the 
drug is preferentially released in the intestinal tract; hydrophobic excipients having a 
weak acidic group are preferable because they are less soluble in water at low pH, but 
soluble in neutral and alkaline regions due to the ionization of the acidic group; under 
the control of this pH dependence, the delayed-release dosage form, which passes from 
the stomach into the higher pH environment of the upper small intestine, would 
experience increased drug release; for this purpose, CMEβCD has been developed to 
exhibit pH-dependent solubility for use in selective dissolution of the drug-CD complex 
(24,50). The release property of the CD conjugates can be classified as a delayed release 
(30). 
 
Colon specific. The oral administration of PDL - a typical glucocorticoid with 
significant systemic side effects (higher PDL plasma concentrations) - was compared 
with its CD conjugate. The results showed that PDLsuc-αCD conjugate (PDL prodrug) 
is useful as a delayed-release system. Thus, their application is advantageous for colon-
specific delivery due to the decrease of the systemic side effect, while maintaining the 
therapeutic effect (86). 
Other authors also have designed CD conjugates for delayed-release systems; 
the KP, a NSAID, was covalently bound to one of the αCD’s primary hydroxyl groups. 
The release behavior of the resulting conjugate was investigated, in vitro and using rats. 
The repeated- and prolonged-release systems based in the CD conjugate also were 
prepared. The repeated-release system of KP was prepared by combining the CD 
conjugate with a fast-release fraction such as the KPHPβCD complex. The prolonged-
release system of KP was prepared by combining the CD conjugate with a slow-release 
fraction such as the KP-EC solid dispersion. These CD conjugate-based approaches 
may be useful for controlled release (30). 
Formation of prodrugs has improved the delivery properties of the parent drug 
molecule (87-89).  
Activated by the microbial enzymes in the large intestine, 5-aminosalicylic acid 
(5-ASA) is released from CD-5-ASA at a controlled rate. These results showed the oral 
administration of 5-ASA gives much higher plasma and urine concentrations of 5-ASA 
than CD-5-ASA, and the conjugate can lower the plasma concentration of 5-ASA. The 
lower concentration is attributable to the passage of the conjugate through the stomach 
and small intestine without significant degradation or absorption, followed by the 
degradation of the conjugate site-specifically in the cecum and colon (87). 
The release behavior of the 5-fluorouracil-1-acetic acid (5-FUA) - βCD 
conjugate, through ester or amide linkage was investigated in enzymatic solutions and 
rat cecal contents. The results have shown that the 5-FUA-βCD ester conjugate may 
survive passing through stomach and small intestine, and the release of 5-FUA occurs 
preferentially in cecal and large intestinal tracts of rats after the fermentation of βCD to 
small oligosaccharides (88).  
 
Others. The in vivo release behavior of antiinflammatory drug (4-
biphenylylacetic acid - BPAA) from its CD ester and amide-type prodrugs in rat 
intestines, together with the anti-inflammatory effect after oral administration of the 
prodrugs was evaluated. The results suggest that CD/drug prodrugs can survive passage 
through stomach and small intestine, and drug release is triggered by enzymatic 
degradation of the CD ring in the colon. The ester prodrugs, particularly the α and yCD 
forms, are subject to ring opening followed by hydrolysis to the maltose and triose 
conjugates. The ester bond of the small saccharide conjugates is subsequently 
hydrolyzed to form BPAA which is absorbed from the rat cecum and colon. On the 
other hand, the amide prodrugs are hydrolyzed to small saccharide conjugates, but the 
amide bond resists the hydrolysis and thus resides as the maltose conjugate in these 
tracts. This type of drug release is essentially classified as delayed release with a fairly 
long lag time (89). 
Physic and pharmaceutical properties of CD conjugates in which a drug is 
covalently bonded to the CD may be significantly different from those of the inclusion 
complexes. The preparation of conjugated ibuprofen (IB)- and indomethacin (IN)-βCD 
as prodrugs and the preparation of linked poly(ethylene glycol)-βCD in conjugation 
with IB or IN were reported. The hydrolysis of CD linked to poly(ethylene glycol) (Mw 
= 600) containing IB and IN was studied in aqueous buffer solutions at physiological 
conditions. In comparison, the hydrolysis of IB in this prodrug/drug compound at the 
first five hours is higher than IN (28). 
The binding of the bisphosphonate-derivatized βCD conjugate to hydroxyapatite 
(HA), its complexation with dexamethasone (Dex), and the in vitro drug release profile 
of the complex immobilized on HA surfaces were investigated. The βCD-based delivery 
system alendronate-β-cyclodextrin conjugate (ALN-βCD) shows very strong binding to 
HA, and it formed a molecular inclusion complex with Dex (1:1). In an in vitro release 
study, the ALN-β-CD/Dex complex bound to HA could gradually release Dex upon 
repeated extraction with phosphate buffer saline. Potentially, this delivery system may 
be formulated into a topical formulation with different therapeutic agents and applied in 
clinical treatment of a variety of diseases in the oral cavity (90). 
The capacity of CDs polymers to modulate (to enhance or to retard) the release 
of a model drug (diflunisal, DF) from HPMC matrices was studied: the incorporation of 
DFβCD inclusion complex enhanced the release of the drug when compared with its 
physical mixture. In this study, it was also possible to modify the drug release from 
HPMC matrices by incorporating βCDPs with different solubilities; soluble polymers 
promoted drug release while insoluble ones delayed it. This fact can be explained 
mainly by inclusion of the drug within the CD cavities which is present in the polymeric 
structure (91).  
 
 
Nanotechonology 
 
More recently CDs have also been used in nanotechonology as drug delivery and 
carrier systems (10,46,92) Various studies have been developed in this area involving 
CDs in nanometric particles in order to design versatile delivery systems that can 
encapsulate drugs with different physicochemical properties (i.e. hydrophilic and 
hydrophobic). The most popular formation of the nanoparticles (NPs) containing CDs 
consists of the incorporation of previously formed drug-CD inclusion complexes into 
polymer NPs. Thus, the presence of CDs generally results in an increase in lipophilic or 
hydrophilic drug loading. Other nanocarriers may result from the design of amphiphilic 
CDs that self-assemble in the form of stable NPs (21,93) and also from the design of 
CD conjugates that can transport the drug encapsulated or connected to the block  
(10,30,46). The CDs may be excellent building blocks for the synthesis of safe and 
water-soluble polymers for drug delivery. However, due to the multi-functionality of 
CD molecules, most CD-containing polymers that have been extensively studied are 
heavily cross-linked. The structures of these polymers are complex and make their 
characterization difficult (94).  
 
Nanoparticles 
 
Solid lipid nanoparticles (SLN) containing hydrocortisone and progesterone 
alone or hydrocortisone and progesterone/βCD or HPβCD complexes were prepared, 
and the release of both drugs was lower when they were incorporated as inclusion 
complexes than as free molecules after oral administration (95). Another study for the 
same route of administration tested two useful techniques for NPs preparation using 
CDs in the design of colloidal carriers. The first possibility consisted on increasing the 
loading capacity of poly(isobutyl cyanoacrylate) nanospheres prepared by anionic 
polymerization, employing HPβCD, and the second possibility consisted on the 
spontaneous formation of either nanocapsules or nanospheres by nanoprecipitation of 
amphiphilic CD diesters. The new amphiphilic derivatives do not need any 
polymerization process to form NPs, nanocapsules, or nanospheres presenting a high 
loading capacity of the lipophilic or even hydrophilic drugs (96). In order to improve 
the aqueous solubility and bioavailability of ONO-8713, the method of co-grinding 
using CDs and CD derivatives in an attempt to prepare crystalline NPs was applied. The 
results show that this method could be applied effectively as a NPs preparation method 
for poorly water soluble drugs, being the amount of water used, the CD content in the 
mixture, and the interaction between drug and CDs significant factors for the NP 
formation process (97). Some of the most successful cationic polymers bear CD rings 
linked together by cationic spacer chains. The novel per(6-guanidino-6-deoxy)CDs 
display very strong binding toward phosphorylated and very weak binding toward non-
phosphorylated guest molecules. Furthermore, they interact with DNA and actually 
compact it into NPs, a basic requirement for its entry inside cells. It was clearly shown 
that guanidinylated CDs bind tightly to phosphorylated substrates. Therefore, 
investigation of the binding behavior toward DNA was considered, as shown recently, 
that amino CDs can be used in DNA transfection studies (98). Other authors studied the 
interaction of the isophorone diisocyante with HPβCD showing that the enhanced molar 
ratio of isophorone diisocyanate to HPβCD could increase the reaction ratio between the 
hydroxyl groups of HPβCD and isocyanate groups of isophorone diisocyanate. An 
increase on the cross-linked polymeric network formation and its cross-link degree was 
also demonstrated. This fact might reduce the spaces in cross-linked polymeric matrices 
for the diffusion of drug (nimodipine, NI) and consequently to increase the entrapment 
efficiencies of nanocapsules decreasing the NI release rate. HPβCD-based nanocapsules 
showed a slower NI release rate when compared to chitosan based nanocapsules due 
probably to the fact that the drug can be included into the HPβCD cavity increasing the 
molecular interactions between them (99). CDs have also been used in NPs to overpass 
problems resulting from proteins oral administration. The very low bioavailability of 
these substances results mainly from their susceptibility to proteolysis and inability to 
cross biologic membranes. This problem can be solved through CD complexation thus 
improving the protein therapy by stabilizing them against aggregation, thermal 
denaturation and degradation. Proteins hydrophilic characteristics and size may be a 
problem in the inclusion process. However, inclusion of the hydrophobic side chains 
into the βCD cavity leads to the formation of non-covalent inclusion complexes, and 
CDs’ ability to sequester hydrophobic moieties helps in improving the stability of 
proteins. It was also observed that the NPs displayed good insulin encapsulation 
efficiency and pH-dependent release profile at acidic/alkaline conditions without 
changing their biological activity (100). Zhang et al. reported that alginate/chitosan NP 
system exhibited an effective protection and controlled the release of insulin complexes 
with cationic βCD polymers (CP-βCDs). An oral insulin formulation of CP-βCDs-
insulin-loaded alginate/chitosan NPs has shown a significantly higher (40%) cumulative 
insulin release in simulated intestinal fluid than that without CP-βCDs (18%). This fact 
can be explained because the insulin was mainly retained in the core of the NPs and 
well protected against degradation in simulated gastric fluid (101). The preparation, 
characterization, and evaluation of the NPs formed by the copolymer of methyl vinyl 
ether and maleic anhydride (Gantrez® AN) and CDs, including βCD, HPβCD and 6-
monodeoxy-6-monoamino-β-cyclodextrin (NHβCD), were also described. The 
incorporation of CDs in Gantrez® AN NPs increased the bioadhesive capacity of 
poly(anhydride) NPs. This fact may be related with the high content of hydroxyl groups 
in the resulting NPs which can increase the possibilities of these carriers to interact with 
mucosa components by means of hydrogen bonds. In addition, the high bioadhesive 
capacity for 2-hydroxypropl-β-cyclodextrin-poly(anhydride) NPs (HPβCD-NP) and 
NHβCD-poly(anhydride) NPs (NHβCD-NP) could be related with their rough 
morphology and, thus, a higher specific surface than for smooth NPs. Finally, from in 
vivo imaging studies, it was observed that the HPβCD-NP remained in the gut not 
showing any evidence of translocation of distribution to other animals organs (male 
wistar rats) (102). The paclitaxel (PTX) from PTXβCD NP and PTXHPβCD NP 
(poly(anhydride) NPs) shows high relative oral bioavailability (>80%) while for 
PTXNHβCD NPs the oral bioavailability was found to be 18%. This important 
difference observed when aminated CD was used can be explained by two reasons: (1) 
the presence of amino groups would decrease or suppress the inhibitory effect over the 
P-glycoprotein that has been observed for CDs and (2) the rapid release of an important 
fraction of PTX (about 70% in less than 30 min) from NPs of PTXNHβCD when 
dispersed in a stomach simulated fluid. The results corroborate the synergistic effect 
obtained by the combination of bioadhesive NPs and CDs on the oral bioavailability of 
PTX. In addition, when the PTX was encapsulated in poly(anhydride) NPs as complex 
with either HPβCD or βCD, the relative oral bioavailability of this anticancer drug was 
calculated to be higher than 80% (103). The addition of relatively small amounts of the 
water-soluble HPyCD to aqueous yCD formulations increases the complexation 
efficiency (CE) of yCD and reduces the turbidity of yCD solutions. It was hypothesized 
that the observed effect was somehow related to formation of yCD and HPyCD NPs. 
Thus, the purpose of this work was to investigate further the solubilizing effects of yCD, 
HPyCD, and yCD/HPyCD mixtures and their formation of nanosize aggregates. The 
results show that the mixtures of yCD and HPyCD have synergistic solubilizing effects 
on hydrocortisone and Dic. Both indomethacin and amphotericin B have very low 
affinity for yCD and HPyCD as observed by their very low CE value, indicating that 
only about 2-7% of the CD molecules in the solution are forming complexes with these 
drug molecules.  The parent αCD, βCD and yCD; their derivatives, such as HPβCD and 
HPyCD; and complexes self-assemble to form nanoscale aggregates in aqueous 
solutions. At CD concentration of about 1% (w/v) or lower, the relative mass 
contribution of these aggregates is less than 0.01%, but it gradually increases with 
increasing CD concentration up to about 5-10% (w/v) when all increase in dissolved 
drug/CD complexes is in the form of CD aggregates. (104).  
 
Conjugates 
 
A new class of CDs conjugated to polymers through covalent bounds has been 
synthesized as nontoxic vectors for the delivery of macromolecules. Some examples are 
described below.  
βCD-based linear polymers extremely soluble in aqueous solution and show low 
toxicity to cultured cells were synthesized and used for the conjugation of camptothecin 
(CPT). Conjugation increased the CPT solubility by more than 3 orders of magnitude. 
These polymer-CPT conjugates have been tested in a xenograft mouse model. Initial 
tumor reduction studies reveal that these conjugates have enhanced efficacy over CPT 
alone and one of the commercial analogues of CPT (irinotecan). By comparison, the 
CD-containing polymer conjugates of CPT gave median tumor sizes that ranged from 
10 to 12% of the median size of the tumors in the control group (94). CD derivatives 
conjugated with saccharide(s) were synthesized in order to be drug carrier molecules 
capable of specific cell recognition and might be useful as targeting drug delivery 
systems. It was possible to synthesize mono-glucose-branched CDs, which had an 
appropriate spacer between the βCD and a glucose moiety. These mono-glucose-
branched CDs indicated significantly high association constants for doxorubicin (DXR) 
in the range of 105-106 M-1. The introduction of an appropriate spacer can also enhance 
the CD´s inclusion ability for drugs having an aromatic ring like DXR (105). Innovative 
system resulting from the association between a CD polymer (polyβCD) and 
amphiphilic cationic connectors was developed. The results showed that CDs polymers 
(polyβCD) complexed with adamantly cationic derivatives (Ada) constitute novel and 
efficient nonviral vectors for gene delivery (106). Porphyrin-βCD conjugate was used 
for PTX delivery and porphyrin-yCD conjugate for DXR transport. This study presented 
a novel versatile supramolecular “Lego system” suitable for the combined cancer 
therapy, which is based on the effective drug binding as inclusion complexes with 
porphyrin-CD carriers and on known tumor targeting by porphyrin macrocycles (10). 
Davis’s group has successfully conjugated low molecular weight polyethylenimine 
(PEI; Mw 600) with βCD. The resultant PEI600-CD polymeric conjugates (PC) with the 
molar ratio of 1:1 are capable of mediating efficient gene transfection in cultured 
neurons and in the central nervous system. Incorporating anticancer drugs onto PEI600-
CD conjugates may endow them with new and interesting properties for great 
applications in combination therapy. A new locally injectable bifunctional delivery 
system (FU-PEI600-CD, FPC) of an anticancer drug and a gene was developed by 
combining PEI600-CD (PC) and 5-Fluoro-2′-deoxyuridine (FdUrd). The effects of the 
developed FPC on cancer cells were systematically investigated through a series of 
experiments including cancer cell viability, invasion, migration, cell cycle, apoptosis, 
and uptake of FPC. In addition, in vitro and in vivo gene transfection was also 
conducted. In comparison with an equivalent dose of FdUrd, the antitumor therapeutic 
effects were largely enhanced by FPC, which still exhibited good gene expression 
efficiency. Thus, the prepared bifunctional FPC composed of βCD, low molecular 
weight PEI, and FdUrd showed improved bioavailability, significantly stronger ability 
to induce apoptosis, and more efficient cellular uptake than equivalent dose of free 
FdUrd. Such bifunctional FPC with good ability to deliver drugs and transfer genes may 
have great potential applications for combination therapy of glioma cancer (107). 
Other delivery systems 
 
The efficacy of carboplatin (Carb) or 5-fluorouracil (5-FU) on MCF-7 and 
MDA-MB 231 breast cancer cell lines, either alone or in combination was improved 
after MeβCD pretreatment. The results obtained suggest that MeβCD pretreatment 
enhances the susceptibility of breast cancer cells towards low doses of Carb or 5-FU by 
increasing the intracellular accumulation of these drugs. These data provide a biological 
basis for the potential therapeutic application of MeβCD in cancer chemotherapy in 
combination with other conventional cytotoxic drugs (108). The design and in vitro and 
in vivo evaluations of polypseudorotaxanes of pegylated insulin with CDs as a 
sustained-release system was reported. The pegylated insulin forms 
polypseudorotaxanes with α and γCD in a similar manner as poly(ethylene glycol). The 
polypseudorotaxanes prepared are less soluble in water, and the release rate of the 
pegylated drug can be controlled by changing the threading and dethreading rates of the 
polypseudorotaxanes by adjustment of administration conditions such as amount of 
injection and concentration of CDs in the medium (109). Later a new slow-release 
system of pegylated lysozyme/CD polypseudorotaxanes was developed. This 
technology suggests that it may be applicable as a new method of pegylated proteins, 
peptides, and low-molecular weight drugs slow-release systems. For that, PEG (Mw 
2,200) chains were introduced into lysozyme molecules and formed 
polypseudorotaxanes with α and γCD, by inserting one PEG chain in the αCD cavity 
and two PEG chains in the γCD cavity. The results demonstrated that the pegylated 
lysozyme/CD polypseudorotaxanes were less soluble in water, and the release rate of 
the pegylated protein decreased in the order of the pegylated lysozyme>the γCD 
polypseudorotaxane>the αCD polypseudorotaxane (110). The formation of the complex 
constituted by genistein (Gen) with the modified amphiphilic CD SC6OH at 1:1 molar 
ratio in water medium demonstrated that Gen molecules are shown to be not included 
inside the SC6OH cavity but to interact with the side chains of SC6OH nanoaggregates. 
The lack of inclusion of the guest molecules inside the host macrocycle was confirmed, 
in solid phase, by monitoring the significant differences in the spectral features of the 
FTIR–ATR spectrum of complex. The evidences found in this study shed light on the 
complexation of drugs in host nanocarriers at solid phase and open the way to detect the 
supramolecular interactions in complexed species host/drug and host/drug/receptor in 
targeted drug delivery (111). Quaternization of βCD grafted with chitosan (CD-g-CS) 
using glycidylt rimethyl ammonium chloride leads to water-soluble CD-g-CS derivative 
(QCD-g-CS). All QCD-g-CSs showed self-aggregates behavior in water while 
quaternized native chitosan did not. The surfactant-like or micelle-like structures of 
QCD-g-CS are firstly presented with the βCD moiety inner core and the quaternary 
ammonium moiety outer shell. Atomic force microscopy (AFM) and transmission 
electron microscopy images revealed that self-aggregates of the QCD-g-CS were 
spherical shape. It was found that the particle sizes increased with an increasing in 
degrees of substitution (DS) (βCD moiety) into the CS backbone, leading to large 
aggregation in water. The stronger mucoadhesive strength, the higher degree of 
quaternization (DQ), zeta-potential, slope value and the lower critical concentration 
value were observed. In this study, DQ played an important role on mucoadhesive 
property while the cytotoxicity did not correlate with DQ (112). 
 
 
 
 
Conclusion 
 
This review highlights the beneficial applications of the CDs and their 
derivatives on the solubility / dissolution rate and bioavailability enhancement of poorly 
water-soluble drugs. Their ability for immediate and modified (to prolong or to delay) 
release of drugs from solid dosage forms, either as complexes or as nanotechnology 
carriers, is also demonstrated. CDs may also enhance drug absorption across biological 
barriers. The increased number of CD derivatives / carriers that have been synthesized 
up to now demonstrates the CDs versatility on the oral dosage forms formulations. The 
research accomplished that has contributed for the great success of those formulations, 
may be the base of new achievements on oral controlled release. Although a high 
number of studies using CDs and their derivatives have been reported, there is plenty of 
room for new discoveries and applications on controlled release of oral pharmaceutical 
dosage forms especially at the nanotechnology level and on the delivery of peptides and 
proteins. CDs may be a useful strategy in life cycle management of medicines. 
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